Howard E. Gendelman, M.D. | |
---|---|
Born | March 18, 1954 Philadelphia, Pennsylvania, U.S. |
Nationality | American |
Alma mater | Muhlenberg College (B.S.) Pennsylvania State University College of Medicine (M.D.) |
Known for | HIV research, Parkinson's research, neuroimmune-pharmacology |
Awards | Startup of the Year 2022 UNeMed; Nebraska Coalition for Lifesaving Cures' 2022 Life Saver Award; 2018 Jewish Federation of Omaha Humanitarian of the Year Award; 2017 Society on NeuroImmune Pharmacology Lifetime Achievement Award; International Society for NeuroVirology's 2016 Pioneer in NeuroVirology; 2000 J. William Fulbright Research Scholar; and others |
Scientific career | |
Fields | Virology, neuroimmunology, neuroscience, pharmacology, therapeutics |
Institutions | Current: University of Nebraska Medical Center Previous: Henry M. Jackson Foundation for the Advancement in Military Medicine Walter Reed Army Institute of Research Uniformed Services University of the Health Sciences Center Johns Hopkins University Albert Einstein College of Medicine |
Website | https://www.unmc.edu/pharmacology/faculty/primary-faculty/gendelman/ |
Howard E. Gendelman (born March 18, 1954) is an American physician-scientist whose research intersects the disciplines of neuroimmunology, pharmacology, and infectious diseases. Gendelman was born in Philadelphia, Pennsylvania. His research is focused on harnessing immune responses for therapeutic gain in HIV/AIDS and Neurodegenerative disease. [1] He is the Margaret R. Larson Professor of infectious diseases and internal medicine at the University of Nebraska Medical Center (UNMC) in Omaha. [2]
He is married with three children and seven grandchildren. [3]
Gendelman was born in Philadelphia, on March 18, 1954. He attended Muhlenberg College in Allentown, Pennsylvania, where he graduated with a bachelor's degree in Natural Sciences and Russian Studies in 1975. [3] He completed his doctorate of medicine at the Pennsylvania State University-Hershey Medical Center in 1979. [3] He then completed a residency in Internal medicine at Montefiore Hospital, Albert Einstein College of Medicine in 1982, and he was a Clinical and Research Fellow in Neurology and Infectious Diseases at the Johns Hopkins Hospital in Baltimore from 1982 to 1985. [3]
Gendelman worked at the National Institute of Allergy and Infectious Diseases during the height of the HIV/AIDS pandemic. [4] Gendelman also occupied senior faculty and research positions at the Johns Hopkins Medical Institutions, the Uniformed Services University of the Health Sciences Center, the Walter Reed Army Institute of Research, and the Henry M. Jackson Foundation for the Advancement in Military Medicine before joining the faculty of UNMC in March 1993. He retired from the US Army with the rank of Lieutenant Colonel. He established the Center for Neurovirology and Neurodegenerative Disorders at UNMC in 1997, [5] which evolved into UNMC's current Department of Pharmacology and Experimental Neuroscience in 2004. [6] In 2000, he was awarded a Fulbright to do research at the Weizmann Institute of Science in Rehovot, Israel [7] [8]
Gendelman's research explores the role of mononuclear phagocytes (monocytes, macrophages, microglia, and dendritic cells) as viral reservoirs, perpetrators of disease, and depots for nanoformulated drug delivery. His work was foundational to building a field of investigation focused on lentiviral pathogenesis, diagnostics, and therapeutics. These advancements in immune transformation have led to new and effective management of neurodegenerative disease progression. Gendelman and his research team were among the first to develop laboratory assays for establishing viral tropism for mononuclear phagocytes, and they were the first to demonstrate that infected and immune activated mononuclear phagocytes release viral and cellular toxins that damage the nervous system. [9] [10] [11]
Gendelman's group was among the first to reverse HIV-dementia in an infected person using combination antiretroviral therapy (cART), and they developed scores of rodent models to mimic HIV/AIDS end-organ disease. [12] [13] [14] He coined the term long-acting slow effective release ART (LASER ART). These works led to polymer discovery, targeted drug delivery to viral reservoirs, and reduction of residual virus in lymphoid organs. His Nebraska-based research group, along with a team at Temple University, was also the first to combine HIV reservoir-targeted LASER ART and CRISPR-Cas9 to eliminate chronic viral infection from infected animals. [15] This curative approach (published in Nature Communications, 2019) received considerable attention in establishing a novel translational pathway for HIV eradication. [16] [17] [18] This work followed the first ultra-long acting nanocrystal prodrug and the world's first HIV vaccine mimetic [19] [20] (in Nature Materials, 2020). His work with cell-based drug delivery born out of nanoparticle-mononuclear phagocyte interactions has inspired broad pharmaceutical interest; in turn, Gendelman led the establishment of the Nebraska Nanomedicine Production Plant, [21] a biotechnology good manufacturing practices (cGMP) initiative, to position research for clinical translation in the development of long acting nanoformulated ART at UNMC. He also co-founded Exavir Therapeutics, Inc., [22] a biotechnology company developing therapies towards and cure for HIV/AIDS.
Gendelman was the first to pharmacologically transform effector into regulatory T cells to halt the progression of Parkinson's disease. [23] [24] Phase II investigation began in early 2021 after successful phase I investigations [25]
Gendelman has written or edited 17 books and monographs (including multiple editions of the textbooks The Neurology of AIDS [26] and Neuroimmune Pharmacology [27] ). He was the founding Editor-in-Chief of the Journal of Neuroimmune Pharmacology.
Parkinsonism is a clinical syndrome characterized by tremor, bradykinesia, rigidity, and postural instability. Both hypokinetic as well as hyperkinetic features are displayed by Parkinsonism.These are the four motor symptoms found in Parkinson's disease (PD) – after which it is named – dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD), and many other conditions. This set of symptoms occurs in a wide range of conditions and may have many causes, including neurodegenerative conditions, drugs, toxins, metabolic diseases, and neurological conditions other than PD.
This is a timeline of HIV/AIDS, including but not limited to cases before 1980.
Following infection with HIV-1, the rate of clinical disease progression varies between individuals. Factors such as host susceptibility, genetics and immune function, health care and co-infections as well as viral genetic variability may affect the rate of progression to the point of needing to take medication in order not to develop AIDS.
The neuroimmune system is a system of structures and processes involving the biochemical and electrophysiological interactions between the nervous system and immune system which protect neurons from pathogens. It serves to protect neurons against disease by maintaining selectively permeable barriers, mediating neuroinflammation and wound healing in damaged neurons, and mobilizing host defenses against pathogens.
The human immunodeficiency virus (HIV) is a retrovirus that attacks the immune system. It can be managed with treatment. Without treatment it can lead to a spectrum of conditions including acquired immunodeficiency syndrome (AIDS).
The central nervous system (CNS) controls most of the functions of the body and mind. It comprises the brain, spinal cord and the nerve fibers that branch off to all parts of the body. The CNS viral diseases are caused by viruses that attack the CNS. Existing and emerging viral CNS infections are major sources of human morbidity and mortality.
Janice Ellen Clements is vice dean for faculty at the Johns Hopkins School of Medicine and the Mary Wallace Stanton Professor of Faculty Affairs. She is a professor in the departments of Molecular and Comparative Pathobiology, Neurology, and Pathology, and has a joint appointment in molecular biology and genetics. Her molecular biology and virology research examines lentiviruses and how they cause neurological diseases.
Gladstone Institutes is an independent, non-profit biomedical research organization whose focus is to better understand, prevent, treat and cure cardiovascular, viral and neurological conditions such as heart failure, HIV/AIDS and Alzheimer's disease. Its researchers study these diseases using techniques of basic and translational science. Another focus at Gladstone is building on the development of induced pluripotent stem cell technology by one of its investigators, 2012 Nobel Laureate Shinya Yamanaka, to improve drug discovery, personalized medicine and tissue regeneration.
In biology, a pathogen, in the oldest and broadest sense, is any organism or agent that can produce disease. A pathogen may also be referred to as an infectious agent, or simply a germ.
HIV/AIDS research includes all medical research that attempts to prevent, treat, or cure HIV/AIDS, as well as fundamental research about the nature of HIV as an infectious agent and AIDS as the disease caused by HIV.
Kalipada Pahan is a professor of Neurological Sciences, Biochemistry and Pharmacology, and the Floyd A. Davis, M.D., Endowed Chair in Neurology at the Rush University Medical Center. He is also a research career scientist at the Department of Veterans Affairs, Jesse Brown VA Medical Center. He is an eminent Indian American neuroscientist involved in translational research on multiple sclerosis, Parkinson's disease, Alzheimer's disease, dementia, and Batten disease. He is well known for his research on statins, cholesterol-lowering drugs. He first explored the application of statins in suppressing the inflammatory events in microglia, astroglia and macrophages. This finding has revolutionized the research on statin drugs. Later, his lab has shown that statins may be beneficial in protecting neurons and improving locomotor activities in Parkinson's disease by suppressing the activation of p21/Ras. His lab is also famous for research on cinnamon where they have described that this commonly-used natural spice may be beneficial for different brain disorders including improving memory and learning of poor learners. Recently his lab has delineated a unique crosstalk between fat and memory in which the lipid-lowering transcription factor PPARalpha controls the formation of hippocampal memory via transcriptional regulation of CREB, suggesting a possible reason for the connection between excess belly fat and memory loss.
Neuroinflammation is inflammation of the nervous tissue. It may be initiated in response to a variety of cues, including infection, traumatic brain injury, toxic metabolites, or autoimmunity. In the central nervous system (CNS), including the brain and spinal cord, microglia are the resident innate immune cells that are activated in response to these cues. The CNS is typically an immunologically privileged site because peripheral immune cells are generally blocked by the blood–brain barrier (BBB), a specialized structure composed of astrocytes and endothelial cells. However, circulating peripheral immune cells may surpass a compromised BBB and encounter neurons and glial cells expressing major histocompatibility complex molecules, perpetuating the immune response. Although the response is initiated to protect the central nervous system from the infectious agent, the effect may be toxic and widespread inflammation as well as further migration of leukocytes through the blood–brain barrier may occur.
Lauren V. Wood is an American allergist, immunologist, and staff physician at the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in Bethesda, Maryland, where she has served as a principal investigator. She is known for conducting studies of vaccines for cancer, Human papillomavirus (HPV), Hepatitis C, and HIV especially for use with children, teens and young adults. She holds the rank of captain in the U.S. Public Health Service (PHS).
M. Juliana “Julie” McElrath is a senior vice president and director of the vaccine and infection disease division at Fred Hutchinson Cancer Research Center and the principal investigator of the HIV Vaccine Trials Network Laboratory Center in Seattle, Washington. She is also a professor at the University of Washington.
Sharon Ruth Lewin, FRACP, FAHMS is an Australian physician who is the inaugural Director of The Peter Doherty Institute for Infection and Immunity. She is also a Professor of Medicine at The University of Melbourne, a National Health and Medical Research Council (NHMRC) Practitioner Fellow, Director of the Cumming Global Centre for Pandemic Therapeutics, and President of the International AIDS Society (IAS).
Pontiano Kaleebu is a Ugandan physician, clinical immunologist, HIV/AIDS researcher, academic and medical administrator, who is the executive director of the Uganda Virus Research Institute.
Ya-Chi Ho is a Taiwanese infectious disease researcher and Associate Professor of Microbial Pathogenesis and Medicine at Yale University. Her research centers on the interaction between HIV and the host's immune system with the ultimate goal of curing HIV/AIDS.
Georgette D. Kanmogne is a Cameroonian American geneticist and molecular virologist and a full professor and vice chair for resource allocation and faculty development within the Department of Pharmacology and Experimental Neurosciences at the University of Nebraska Medical Center in Omaha, Nebraska. Kanmogne's research program focuses on exploring the pathogenesis of neuroAIDS by deciphering the mechanisms underlying blood brain barrier dysfunction and viral entry into the central nervous system. Her research also addresses the lack of HIV therapies that cross the blood brain barrier (BBB) and has played a critical role in the development of nanoparticles encapsulating HIV-drugs that can cross the BBB to prevent viral-mediated neuron death in the brain. Kanmogne collaborates with clinical and basic researchers across America, Cameroon, and West Africa, spanning disciplines from hematology to psychiatry, to explore how viral genetic diversity is correlated with the neurological impact of HIV.
Jasmine R. Marcelin is a Caribbean-American infectious disease physician and an Assistant Professor in the Department of Internal Medicine at the University of Nebraska Medical Center (UNMC). Marcelin is also the Associate Medical Director of the Antimicrobial Stewardship Program and as well as the Co-Director of Digital Innovation and Social Media Strategy at UNMC.
Monica Gandhi is an American physician and professor. She teaches medicine at the University of California, San Francisco (UCSF) and is director of the UCSF Gladstone Center for AIDS Research and the medical director of the San Francisco General Hospital HIV Clinic, Ward 86. Her research considers HIV prevalence in women, as well as HIV treatment and prevention. She has been noted as a critic of some aspects of the COVID-19 lockdowns in the US.